Patents Assigned to Bio-Path Holdings, Inc.
-
Publication number: 20220133775Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.Type: ApplicationFiled: November 18, 2021Publication date: May 5, 2022Applicants: Bio-Path Holdings, Inc., Thomas Jefferson UniversityInventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
-
Publication number: 20210361695Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: ApplicationFiled: December 18, 2020Publication date: November 25, 2021Applicant: Bio-Path Holdings, Inc.Inventor: Peter NIELSEN
-
Patent number: 11041153Abstract: Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide. Methods of treating patients with said delivery systems are also provided.Type: GrantFiled: April 19, 2018Date of Patent: June 22, 2021Assignee: BIO-PATH HOLDINGS, INC.Inventor: Ana Tari Ashizawa
-
Patent number: 10927379Abstract: Provided herein are methods of treating a cancer in a patient comprising administration of an effective amount of a nuclease-resistant polynucleotide that hybridizes to the translation initiation site of a Grb2 nucleic acid in the patient and either a Bcr-Abl tyrosine kinase inhibitor (e.g., dasatinib) or a cytidine analogue (e.g., decitabine or cytarabine). The cancer may be Ph+ and/or Bcr-Abl positive chronic myelogenous leukemia or acute myeloid leukemia or myelodysplastic syndrome.Type: GrantFiled: September 15, 2017Date of Patent: February 23, 2021Assignee: BIO-PATH HOLDINGS, INC.Inventor: Ana Tari Ashizawa
-
Patent number: 10898506Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: GrantFiled: May 30, 2019Date of Patent: January 26, 2021Assignee: BIO-PATH HOLDINGS, INC.Inventor: Peter Nielsen
-
Publication number: 20200113928Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: ApplicationFiled: May 30, 2019Publication date: April 16, 2020Applicant: Bio-Path Holdings, Inc.Inventor: Peter NIELSEN
-
Publication number: 20200038429Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.Type: ApplicationFiled: April 19, 2018Publication date: February 6, 2020Applicants: Bio-Path Holdings, Inc., Thomas Jefferson UniversityInventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
-
Patent number: 10335428Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: GrantFiled: July 21, 2017Date of Patent: July 2, 2019Assignee: BIO-PATH HOLDINGS, INC.Inventor: Peter Nielsen
-
Publication number: 20180161360Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: ApplicationFiled: July 21, 2017Publication date: June 14, 2018Applicant: Bio-Path Holdings, Inc.Inventor: Peter NIELSEN
-
Patent number: 9744187Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: GrantFiled: October 14, 2016Date of Patent: August 29, 2017Assignee: BIO-PATH HOLDINGS, INC.Inventor: Peter Nielsen
-
Publication number: 20170106010Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.Type: ApplicationFiled: October 14, 2016Publication date: April 20, 2017Applicant: Bio-Path Holdings, Inc.Inventor: Peter NIELSEN
